Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
10-12 December, 2025
Saudi International Ex...Saudi International Expo
Not Confirmed
Not Confirmed
10-12 December, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
10-12 December, 2025
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
DDL Conference
Not Confirmed
Contact SupplierDDL Conference
Industry Trade Show
Not Confirmed
10-12 December, 2025
Saudi International Ex...Saudi International Expo
Industry Trade Show
Not Confirmed
10-12 December, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
10-12 December, 2025
Digital content
NEWS #PharmaBuzz
20 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/graviton-bioscience-to-present-selective-rock2-obesity-data-at-8th-annual-evercore-healthconx-conference-302622251.html
01 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/01/2906636/0/en/Ovid-Therapeutics-and-Graviton-Bioscience-Announce-Topline-Data-from-a-Phase-1-Clinical-Trial-Studying-OV888-GV101-Capsule-a-Potential-First-In-Class-Therapy-for-Cerebral-Cavernous.html
01 Feb 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/graviton-bioscience-announces-strategic-investment-from-sanofi-to-advance-development-of-the-next-generation-of-selective-rock2-inhibitors-302049773.html
01 May 2023
// Max Bayer FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/ovid-snaps-rock2-inhibitor-sam-waksal-led-biotech-continuing-climb-through-neurological
Drugs in Development
Details:
GV101 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Overweight.
Lead Product(s): GV101,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 20, 2025
Lead Product(s) : GV101,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GV101 in Healthy Obese Participants
Details : GV101 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Overweight.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2025
Details:
OV888 (GV101) is an investigational small molecule capsule, works by inhibiting Rho-associated coiled-coil containing protein kinase 2 receptor for the treatment of cerebral cavernous malformations.
Lead Product(s): GV101,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: Ovid Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2024
Lead Product(s) : GV101,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Ovid Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Ovid and Graviton Announce Data for OV888/GV101 in Cerebral Cavernous Malformations
Details : OV888 (GV101) is an investigational small molecule capsule, works by inhibiting Rho-associated coiled-coil containing protein kinase 2 receptor for the treatment of cerebral cavernous malformations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2024
Details:
Through financing, Sanofi gains a right of first negotiation to license compounds like GV101 for various indications, including immunological and metabolic syndrome.
Lead Product(s): GV101,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 01, 2024
Lead Product(s) : GV101,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Undisclosed
Deal Type : Financing
Graviton Receives Sanofi Investment to Advance Next-Generation ROCK2 Inhibitors
Details : Through financing, Sanofi gains a right of first negotiation to license compounds like GV101 for various indications, including immunological and metabolic syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 01, 2024
Details:
The collaboration will advance clinical development of GV101, which is currently in a Phase 1 trial, along with other selective, small-molecule compounds from a library of ROCK2 inhibitors, that may penetrate the blood-brain barrier.
Lead Product(s): GV101,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Ovid Therapeutics
Deal Size: $10.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration May 01, 2023
Lead Product(s) : GV101,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Ovid Therapeutics
Deal Size : $10.0 million
Deal Type : Collaboration
Details : The collaboration will advance clinical development of GV101, which is currently in a Phase 1 trial, along with other selective, small-molecule compounds from a library of ROCK2 inhibitors, that may penetrate the blood-brain barrier.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.0 million
May 01, 2023
Details:
GV101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): GV101,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 06, 2021
Lead Product(s) : GV101,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GV101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
